HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate with or without switching to tenofovir alafenamide.

[1]  T. Berg,et al.  The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analog therapy. , 2021, Journal of hepatology.

[2]  Sheng-Nan Lu,et al.  Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir therapy. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  Sheng-Nan Lu,et al.  Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir , 2018, Alimentary pharmacology & therapeutics.

[4]  Y. Liaw,et al.  Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen–negative chronic hepatitis B , 2018, Hepatology.

[5]  M. Manns,et al.  Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen–Negative Patients , 2018, The Journal of infectious diseases.

[6]  T. Hu,et al.  The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients , 2018, Journal of viral hepatitis.

[7]  M. Buti,et al.  96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. , 2018, Journal of hepatology.

[8]  Ding‐Shinn Chen,et al.  Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy , 2018, The Journal of infectious diseases.

[9]  T. Tseng,et al.  Hepatitis B virus–specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation , 2018, The Journal of clinical investigation.

[10]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[11]  Y. Liaw,et al.  Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen-Negative Patients. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  John F. Flaherty,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. , 2016, The lancet. Gastroenterology & hepatology.

[13]  Fares Alahdab,et al.  Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis , 2016, Hepatology.

[14]  John F. Flaherty,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. , 2016, The lancet. Gastroenterology & hepatology.

[15]  M. Kumar,et al.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.

[16]  Sheng-Nan Lu,et al.  Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  A. Ray,et al.  Implications of Efficient Hepatic Delivery by Tenofovir Alafenamide (GS-7340) for Hepatitis B Virus Therapy , 2015, Antimicrobial Agents and Chemotherapy.

[18]  H. Lee,et al.  HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability , 2013, Gut.

[19]  Sheng-Nan Lu,et al.  A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients , 2013, Hepatology International.

[20]  William A. Lee,et al.  Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. , 2013, Molecular pharmaceutics.

[21]  Jia-Horng Kao,et al.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update , 2012, Hepatology International.

[22]  P. Austin,et al.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.

[23]  J. Niu,et al.  Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies , 2011, Cellular and Molecular Immunology.

[24]  C H Chen,et al.  Prevalence and Clinical Implications of Hepatitis B Virus Genotypes in Southern Taiwan , 2003, Scandinavian journal of gastroenterology.

[25]  R. D'Agostino.  Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .